Treatment of Tardive Dyskinesia with Aripiprazole

R. Osorio,Luis Agüera-Ortiz,A. H. D. Mendoza,I. Ramos,Tomás Palomo

DOI: https://doi.org/10.1007/s12640-009-9123-0

IF: 3.9781

2010-05-01

Neurotoxicity Research

Abstract:

What problem does this paper attempt to address?

Increased artemisinin production in Artemisia annua L. by co-overexpression of six key biosynthetic enzymes

Firdaus Qamar,Anuradha Mishra,Kudsiya Ashrafi,Monica Saifi,Prasanta K Dash,Shashi Kumar,M Z Abdin

DOI: https://doi.org/10.1016/j.ijbiomac.2024.136291

Abstract:Malaria remains a global health issue, especially in resource-limited regions. Artemisinin, a key antimalarial compound from Artemisia annua, is crucial for treatment, but low natural yields hinder large-scale production. In this study, we employed advanced transgenic technology to co-overexpress six key biosynthetic enzymes-Isopentenyl Diphosphate Isomerase (IDI), Farnesyl Pyrophosphate Synthase (FPS), Amorpha 4,11-diene Synthase (ADS), cytochrome P450 monooxygenase (CYP71AV1), cytochrome P450 oxidoreductase (AACPR) and artemisinic aldehyde D11 reductase (DBR2)-in A. annua to significantly enhance artemisinin production. Our innovative approach utilized a co-expression strategy to optimize the artemisinin biosynthetic pathway, leading to a remarkable up to 200 % increase in artemisinin content in T1 transgenic plants compared to non-transgenic controls. The stability and efficacy of this transformation were confirmed in subsequent generations (T2), achieving a potential 232 % increase in artemisinin levels. Additionally, we optimized transgene expression to maintain plant growth and development, and performed untargeted metabolite analysis using GC-MS, which revealed significant changes in metabolite composition among T2 lines, indicating effective diversion of farnesyl diphosphate into the artemisinin pathway. This metabolic engineering breakthrough offers a promising and scalable solution for enhancing artemisinin production, representing a major advancement in the field of plant biotechnology and a potential strategy for more cost-effective malaria treatment.
Biotechnological Approaches for Production of Artemisinin, an Anti-Malarial Drug from Artemisia annua L

Jameel M Al-Khayri,Wudali N Sudheer,Vasantha V Lakshmaiah,Epsita Mukherjee,Aatika Nizam,Muthu Thiruvengadam,Praveen Nagella,Fatima M Alessa,Muneera Q Al-Mssallem,Adel A Rezk,Wael F Shehata,Mahesh Attimarad

DOI: https://doi.org/10.3390/molecules27093040

IF: 4.6

2022-05-09

Molecules

Abstract:Artemisinin is an anti-malarial sesquiterpene lactone derived from Artemisia annua L. (Asteraceae family). One of the most widely used modes of treatment for malaria is an artemisinin-based combination therapy. Artemisinin and its associated compounds have a variety of pharmacological qualities that have helped achieve economic prominence in recent years. So far, research on the biosynthesis of this bioactive metabolite has revealed that it is produced in glandular trichomes and that the genes responsible for its production must be overexpressed in order to meet demand. Using biotechnological applications such as tissue culture, genetic engineering, and bioreactor-based approaches would aid in the upregulation of artemisinin yield, which is needed for the future. The current review focuses on the tissue culture aspects of propagation of A. annua and production of artemisinin from A. annua L. cell and organ cultures. The review also focuses on elicitation strategies in cell and organ cultures, as well as artemisinin biosynthesis and metabolic engineering of biosynthetic genes in Artemisia and plant model systems.
Developmental Iodine Deficiency and Hypothyroidism Impair Neural Development, Upregulate Caveolin-1, and Downregulate Synaptotagmin-1 in the Rat Cerebellum

Yi Wang,Jiapeng Zhong,Wei Wei,J. Gong,J. Dong,Fei Yu,Yuan-Zhao Wang,Jie Chen

DOI: https://doi.org/10.1007/s12011-011-9089-7

IF: 4.081

2011-05-25

Biological Trace Element Research

Abstract:
Molecular Farming in Artemisia annua, a Promising Approach to Improve Anti-malarial Drug Production

Giuseppe Pulice,Soraya Pelaz,Luis Matías-Hernández

DOI: https://doi.org/10.3389/fpls.2016.00329

IF: 5.6

2016-03-18

Frontiers in Plant Science

Abstract:Malaria is a parasite infection affecting millions of people worldwide. Even though progress has been made in prevention and treatment of the disease; an estimated 214 million cases of malaria occurred in 2015, resulting in 438,000 estimated deaths; most of them occurring in Africa among children under the age of five. This article aims to review the epidemiology, future risk factors and current treatments of malaria, with particular focus on the promising potential of molecular farming that uses metabolic engineering in plants as an effective anti-malarial solution. Malaria represents an example of how a health problem may, on one hand, influence the proper development of a country, due to its burden of the disease. On the other hand, it constitutes an opportunity for lucrative business of diverse stakeholders. In contrast, plant biofarming is proposed here as a sustainable, promising, alternative for the production, not only of natural herbal repellents for malaria prevention but also for the production of sustainable anti-malarial drugs, like artemisinin (AN), used for primary parasite infection treatments. AN, a sesquiterpene lactone, is a natural anti-malarial compound that can be found in Artemisia annua. However, the low concentration of AN in the plant makes this molecule relatively expensive and difficult to produce in order to meet the current worldwide demand of Artemisinin Combination Therapies (ACTs), especially for economically disadvantaged people in developing countries. The biosynthetic pathway of AN, a process that takes place only in glandular secretory trichomes of A. annua, is relatively well elucidated. Significant efforts have been made using plant genetic engineering to increase production of this compound. These include diverse genetic manipulation approaches, such as studies on diverse transcription factors which have been shown to regulate the AN genetic pathway and other biological processes. Results look promising; however, further efforts should be addressed toward optimization of the most cost-effective biofarming approaches for synthesis and production of medicines against the malaria parasite.

plant sciences
Production of the antimalarial drug precursor artemisinic acid in engineered yeast

Dae-Kyun Ro,Eric M. Paradise,Mario Ouellet,Karl J. Fisher,Karyn L. Newman,John M. Ndungu,Kimberly A. Ho,Rachel A. Eachus,Timothy S. Ham,James Kirby,Michelle C. Y. Chang,Sydnor T. Withers,Yoichiro Shiba,Richmond Sarpong,Jay D. Keasling

DOI: https://doi.org/10.1038/nature04640

IF: 64.8

2006-04-13

Nature

Abstract:Battling malariaDrug-resistant strains of the malaria parasite are widespread, and as a result mortality due to malaria has increased significantly in recent years. Artemisinin, isolated from the herb Artemisia annua (sweet wormwood), is one drug that shows a high efficacy in killing multi-resistant strains of the parasite. The drug is extremely expensive, and high demand has led to a shortage of artemisinin, available only by extraction from the plant source. Ro et al. now report the development of a yeast strain engineered to carry a cytochrome P450 monooxygenase from A. annua that can produce the drug precursor, artemisinic acid. Artemisinin can be synthesized from this precursor. If the efficiency of this process can be improved, this engineered yeast strain has the potential to alleviate the drug shortage.

multidisciplinary sciences
Enhancing artemisinin content in and delivery from Artemisia annua: a review of alternative, classical, and transgenic approaches

Kaiser Iqbal Wani,Sadaf Choudhary,Andleeb Zehra,M. Naeem,Pamela Weathers,Tariq Aftab

DOI: https://doi.org/10.1007/s00425-021-03676-3

IF: 4.54

2021-07-15

Planta

Abstract:<h3 class="a-plus-plus">Main conclusion</h3>This review analyses the most recent scientific research conducted for the purpose of enhancing artemisinin production. It may help to devise better artemisinin enhancement strategies, so that its production becomes cost effective and becomes available to masses.Malaria is a major threat to world population, particularly in South-East Asia and Africa, due to dearth of effective anti-malarial compounds, emergence of quinine resistant malarial strains, and lack of advanced healthcare facilities. Artemisinin, a sesquiterpene lactone obtained from Artemisia annua L., is the most potent drug against malaria and used in the formulation of artemisinin combination therapies (ACTs). Artemisinin is also effective against various types of cancers, many other microbes including viruses, parasites and bacteria. However, this specialty metabolite and its derivatives generally occur in low amounts in the source plant leading to its production scarcity. Considering the importance of this drug, researchers have been working worldwide to develop novel strategies to augment its production both in vivo and in vitro. Due to complex chemical structure, its chemical synthesis is quite expensive, so researchers need to devise synthetic protocols that are economically viable and also work on increasing the in-planta production of artemisinin by using various strategies like use of phytohormones, stress signals, bioinoculants, breeding and transgenic approaches. The focus of this review is to discuss these artemisinin enhancement strategies, understand mechanisms modulating its biosynthesis, and evaluate if roots play any role in artemisinin production. Furthermore, we also have a critical analysis of various assays used for artemisinin measurement. This may help to develop better artemisinin enhancement strategies which lead to decreased price of ACTs and increased profit to farmers.

plant sciences
Tentative identification and influence of sterols and dimethyl sulf-oxide (DMSO) on the growth and survival of Fusarium roseum.

R. W. Tillman,G. Bean

DOI: https://doi.org/10.2307/3757516

1970-05-01

Mycologia

Abstract:A tentative identification of some sterols present in mycelia and conidia of Fusarium roseum was made by gas liquid chromatography. Sterols identified were ergosterol, 22-dihydroergosterol, and 7-dehydroclionasterol. On ergosterol amended medium (10 mg/liter) conidial production was reduced and the percentage of mature macroconidia was increased from 50 to 70%. After 44 days in distilled water at 4 C, germination of conidia produced on ergosterol amended medium was 16%, whereas, germination of conidia produced on medium without added sterols was 6%. Production of mycelium or conidia was not affected by addition of 0, 5,000, 10,000, or 50,000 ppm DMSO to the medium. However, after 70 days storage in distilled H20 at 4 C, approximately 34% of conidia produced on medium with 0, 5,000, 10,000, and 25,000 ppm DMSO germinated, whereas none of the conidia produced on medium with 50,000 ppm DMSO germinated.
Combined chemical transformation and biological transformation of artemisinin: A facile approach to diverse artemisinin derivatives

Xinna Gao,Yue Bai,Peng Sun,Huimin Gao,Lan Yang,Dong Zhang,Yifan Zhao,Yue Ma

DOI: https://doi.org/10.3389/fchem.2022.1089290

IF: 5.5

2023-01-25

Frontiers in Chemistry

Abstract:Introduction: Artemisinin ( 1 ) is a milestone compound in malaria treatment, and it exhibits a broad scope of bioactivities. Herein, sequential chemo-reduction and biotransformation of artemisinin were undertaken to obtain a series of artemisinin derivatives. Methods: First, 10-deoxyartemisinin ( 2 ) and 9-ene-10-deoxyartemisinin ( 3 ) were synthesized after simple handling with boron trifluoride/diethyl ether and sodium borohydride. Then, biotransformation of 10-deoxyartemisinin was conducted with Cunninghamella echinulata CGMCC 3.4879 and Cunninghamella elegans CGMCC 3.4832, and the transformed products were separated and identified. The antimalarial activity of these products was tested in vitro against Plasmodium falciparum 3D7. Results: Fifteen metabolites (4–18) , including seven novel compounds, were isolated and identified after cultivation. Compounds 2 , 3 , 13 , 15 , 16 , and 18 displayed moderate-to-good antimalarial activity, with a half-maximal inhibitory concentration ranging from 6 to 223 nM. Discussion: This work explored the combination of chemical and biological transformation to develop a co-environmental, efficient, and cost-efficiency synthetic methodology and applied it to synthesize novel derivatives of artemisinin. The association of the two strategies will hopefully provide an abundant source for the development of novel drugs with bioactivities.

chemistry, multidisciplinary
Advanced metabolic engineering strategies for increasing artemisinin yield in Artemisia annua L

Yongpeng Li,Yinkai Yang,Ling Li,Kexuan Tang,Xiaolong Hao,Guoyin Kai

DOI: https://doi.org/10.1093/hr/uhad292

2024-01-02

Abstract:Artemisinin, also known as 'Qinghaosu', is a chemically sesquiterpene lactone containing an endoperoxide bridge. Due to the high activity to kill Plasmodium parasites, artemisinin and its derivatives have continuously served as the foundation for antimalarial therapies. Natural artemisinin is unique to the traditional Chinese medicinal plant Artemisia annua L., and its content in this plant is low. This has motivated the synthesis of this bioactive compound using yeast, tobacco, and Physcomitrium patens systems. However, the artemisinin production in these heterologous hosts is low and cannot fulfil its increasing clinical demand. Therefore, A. annua plants remain the major source of this bioactive component. Recently, the transcriptional regulatory networks related to artemisinin biosynthesis and glandular trichome formation have been extensively studied in A. annua. Various strategies including (i) enhancing the metabolic flux in artemisinin biosynthetic pathway; (ii) blocking competition branch pathways; (iii) using transcription factors (TFs); (iv) increasing peltate glandular secretory trichome (GST) density; (v) applying exogenous factors; and (vi) phytohormones have been used to improve artemisinin yields. Here we summarize recent scientific advances and achievements in artemisinin metabolic engineering, and discuss prospects in the development of high-artemisinin yielding A. annua varieties. This review provides new insights into revealing the transcriptional regulatory networks of other high-value plant-derived natural compounds (e.g., taxol, vinblastine, and camptothecin), as well as glandular trichome formation. It is also helpful for the researchers who intend to promote natural compounds production in other plants species.
High-level semi-synthetic production of the potent antimalarial artemisinin

C. J. Paddon,P. J. Westfall,D. J. Pitera,K. Benjamin,K. Fisher,D. McPhee,M. D. Leavell,A. Tai,A. Main,D. Eng,D. R. Polichuk,K. H. Teoh,D. W. Reed,T. Treynor,J. Lenihan,H. Jiang,M. Fleck,S. Bajad,G. Dang,D. Dengrove,D. Diola,G. Dorin,K. W. Ellens,S. Fickes,J. Galazzo,S. P. Gaucher,T. Geistlinger,R. Henry,M. Hepp,T. Horning,T. Iqbal,L. Kizer,B. Lieu,D. Melis,N. Moss,R. Regentin,S. Secrest,H. Tsuruta,R. Vazquez,L. F. Westblade,L. Xu,M. Yu,Y. Zhang,L. Zhao,J. Lievense,P. S. Covello,J. D. Keasling,K. K. Reiling,N. S. Renninger,J. D. Newman

DOI: https://doi.org/10.1038/nature12051

IF: 64.8

2013-04-01

Nature

Abstract:Saccharomyces cerevisiae is engineered to produce high concentrations of artemisinic acid, a precursor of the artemisinin used in combination therapies for malaria treatment; an efficient and practical chemical process to convert artemisinic acid to artemisinin is also developed.

multidisciplinary sciences
Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid

Dae-Kyun Ro,Mario Ouellet,Eric M Paradise,Helcio Burd,Diana Eng,Chris J Paddon,Jack D Newman,Jay D Keasling

DOI: https://doi.org/10.1186/1472-6750-8-83

2008-11-04

BMC Biotechnology

Abstract:Abstract Background Due to the global occurrence of multi-drug-resistant malarial parasites ( Plasmodium falciparum ), the anti-malarial drug most effective against malaria is artemisinin, a natural product (sesquiterpene lactone endoperoxide) extracted from sweet wormwood ( Artemisia annua ). However, artemisinin is in short supply and unaffordable to most malaria patients. Artemisinin can be semi-synthesized from its precursor artemisinic acid, which can be synthesized from simple sugars using microorganisms genetically engineered with genes from A. annua . In order to develop an industrially competent yeast strain, detailed analyses of microbial physiology and development of gene expression strategies are required. Results Three plant genes coding for amorphadiene synthase, amorphadiene oxidase ( AMO or CYP71AV1 ), and cytochrome P450 reductase, which in concert divert carbon flux from farnesyl diphosphate to artemisinic acid, were expressed from a single plasmid. The artemisinic acid production in the engineered yeast reached 250 μg mL -1 in shake-flask cultures and 1 g L -1 in bio-reactors with the use of Leu2d selection marker and appropriate medium formulation. When plasmid stability was measured, the yeast strain synthesizing amorphadiene alone maintained the plasmid in 84% of the cells, whereas the yeast strain synthesizing artemisinic acid showed poor plasmid stability. Inactivation of AMO by a point-mutation restored the high plasmid stability, indicating that the low plasmid stability is not caused by production of the AMO protein but by artemisinic acid synthesis or accumulation. Semi-quantitative reverse-transcriptase (RT)-PCR and quantitative real time-PCR consistently showed that pleiotropic drug resistance ( PDR ) genes, belonging to the family of ATP-Binding Cassette (ABC) transporter, were massively induced in the yeast strain producing artemisinic acid, relative to the yeast strain producing the hydrocarbon amorphadiene alone. Global transcriptional analysis by yeast microarray further demonstrated that the induction of drug-resistant genes such as ABC transporters and major facilitator superfamily (MSF) genes is the primary cellular stress-response; in addition, oxidative and osmotic stress responses were observed in the engineered yeast. Conclusion The data presented here suggest that the engineered yeast producing artemisinic acid suffers oxidative and drug-associated stresses. The use of plant-derived transporters and optimizing AMO activity may improve the yield of artemisinic acid production in the engineered yeast.

biotechnology & applied microbiology
Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development

Chris J. Paddon,Jay D. Keasling

DOI: https://doi.org/10.1038/nrmicro3240

IF: 88.1

2014-04-01

Nature Reviews Microbiology

Abstract:Key PointsArtemisinin is an antimalarial drug precursor that is produced by the plant Artemisia annua. The supply and price of artemisinin have fluctuated substantially throughout the past decade, owing to inconsistencies in harvest.Artemisinin-based combination therapies (ACTs) are recommended by the WHO as the first-line treatment for uncomplicated malaria. The Semi-synthetic Artemisinin Project aimed to stabilize the supply and price of artemisinin for the development of artemisinin derivatives for use as part of ACTs.Both Escherichia coli and Saccharomyces cerevisiae were engineered using the tools of synthetic biology to produce 25 g per L and 40 g per L, respectively, of the artemisinin hydrocarbon precursor amorphadiene by fermentation.Owing to problems using E. coli, S. cerevisiae was used as the chassis for the industrial-scale production of 25 g per L artemisinic acid by fermentation, which was followed by a chemical conversion process to synthesize artemisinin.Semi-synthetic artemisinin is now produced at industrial scale and has been approved by the WHO for the preparation of approved pharmaceutical compounds for incorporation into ACTs.Lessons learned from the Semi-synthetic Artemisinin Project that are relevant to the development of other pharmaceutical products using metabolic engineering and synthetic biology are summarized.

microbiology
Plant-based nanoparticles targeting malaria management

Pathy B Lokole,Galilée G Byamungu,Paulin K Mutwale,Nadège K Ngombe,Celestin N Mudogo,Rui W M Krause,Christian I Nkanga

DOI: https://doi.org/10.3389/fphar.2024.1440116

2024-08-09

Abstract:Malaria is one of the most devastating diseases across the globe, particularly in low-income countries in Sub-Saharan Africa. The increasing incidence of malaria morbidity is mainly due to the shortcomings of preventative measures such as the lack of vaccines and inappropriate control over the parasite vector. Additionally, high mortality rates arise from therapeutic failures due to poor patient adherence and drug resistance development. Although the causative pathogen (Plasmodium spp.) is an intracellular parasite, the recommended antimalarial drugs show large volumes of distribution and low-to no-specificity towards the host cell. This leads to severe side effects that hamper patient compliance and promote the emergence of drug-resistant strains. Recent research efforts are promising to enable the discovery of new antimalarial agents; however, the lack of efficient means to achieve targeted delivery remains a concern, given the risk of further resistance development. New strategies based on green nanotechnologies are a promising avenue for malaria management due to their potential to eliminate malaria vectors (Anopheles sp.) and to encapsulate existing and emerging antimalarial agents and deliver them to different target sites. In this review we summarized studies on the use of plant-derived nanoparticles as cost-effective preventative measures against malaria parasites, starting from the vector stage. We also reviewed plant-based nanoengineering strategies to target malaria parasites, and further discussed the site-specific delivery of natural products using ligand-decorated nanoparticles that act through receptors on the host cells or malaria parasites. The exploration of traditionally established plant medicines, surface-engineered nanoparticles and the molecular targets of parasite/host cells may provide valuable insights for future discovery of antimalarial drugs and open new avenues for advancing science toward the goal of malaria eradication.
Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic γ-cyclodextrin nanoparticles

Josias Boumbéwendin Gérard Yaméogo,Roseline Mazet,Denis Wouessidjewe,Luc Choisnard,Diane Godin-Ribuot,Jean-Luc Putaux,Rasmané Semdé,Annabelle Gèze

DOI: https://doi.org/10.1016/j.msec.2019.110281

Abstract:Artemisinin and its derivatives are currently recommended by World Health Organization for the treatment of malaria. Severe malaria requires a parenteral administration of artemisinin-based formulations. However, the effective use of artemisinin is limited by the pharmacokinetic characteristics of the drug (low water solubility, poor bioavailability and short half-life). To overcome some of these drawbacks, artemisinin-loaded surface-decorated nanoparticles were prepared by co-nanoprecipitation of γ-cyclodextrin bioesterified with C10 alkyl chains and polyethylene glycol (PEG) derivatives (polysorbate 80 and DMPE-mPEG2000). Using a single dose (1.5 mg kg-1 or 2 mg kg-1) by intravenous administration, we investigated the in vivo pharmacokinetic properties in healthy rats of two types of artemisinin-loaded nanoparticle formulations, namely, nanosphere and nanoreservoir systems versus an ethanolic-aqueous solution of artemisinin as reference. Significantly enhanced pharmacokinetic parameters were obtained with artemisinin-loaded nanoparticles. In comparison to reference formulation, the geometric mean exposures in plasma (AUC0-t) exhibited 2.35 and 3.26-fold increases when artemisinin was loaded in nanoreservoir and nanosphere systems, respectively. Its plasma half-life increased 4.00 and 6.25-fold and its clearance decreased up to 2.5 and 4.72-fold. Artemisinin was successfully administered intravenously by means of surface-decorated amphiphilic γ-cyclodextrin nanostructures and showed a longer elimination half-life with respect to an artemisinin solution in ethanol. Therefore, these systems are likely to provide significant advantages for the intravenous treatment of severe malaria.
Development, characterization, and evaluation of withaferin-A and artesunate-loaded pH-responsive acetal-dextran polymeric nanoparticles for the management of malaria

Deepak Pradhan,Prativa Biswasroy,Manish Ramchandani,Dilip Kumar Pradhan,Rajesh Kumar Bhola,Amit Goyal,Goutam Ghosh,Goutam Rath

DOI: https://doi.org/10.1016/j.ijbiomac.2024.133220

Abstract:Artemisinin and its derivatives have been commonly used to treat malaria. However, the emergence of resistance against artemisinin derivatives has posed a critical challenge in malaria management. In the present study, we have proposed a combinatorial approach, utilizing pH-responsive acetal-dextran nanoparticles (Ac-Dex NPs) as carriers for the delivery of withaferin-A (WS-3) and artesunate (Art) to improve treatment efficacy of malaria. The optimized WS-3 and Art Ac-Dex NPs demonstrated enhanced pH-responsive release profiles under parasitophorous mimetic conditions (pH 5.5). Computational molecular modeling reveals that Ac-Dex's polymeric backbone strongly interacts with merozoite surface protein-1 (MSP-1), preventing erythrocyte invasion. In-vitro antimalarial activity of drug-loaded Ac-Dex NPs reveals a 1-1.5-fold reduction in IC50 values compared to pure drug against the 3D7 strain of Plasmodium falciparum. Treatment with WS-3 Ac-Dex NPs (100 mg/kg) and Art Ac-Dex NPs (30 mg/kg) to Plasmodium berghei-infected mice resulted in 78.11 % and 100 % inhibition of parasitemia. Notably, the combination therapy comprised of Art and WS-3 Ac-Dex NPs achieved complete inhibition of parasitemia even at a half dose of Art, indicating the synergistic potential of the combinations. However, further investigations are necessary to confirm the safety and effectiveness of WS-3 and Art Ac-Dex NPs for their successful clinical implications.
Improved Anti-Malarial Parasite Efficacy with Heparin-Artemisinin Nanoemulsions

Yuxin Zheng,Ning Jiang,Qilong Li,Ruiming Fan,Kexin Zheng,Ziwei Su,Ran Chen,Ying Feng,Yiwei Zhang,Xiaoyu Sang,Qijun Chen

DOI: https://doi.org/10.1016/j.apmt.2024.102470

IF: 8.663

2024-01-01

Applied Materials Today

Abstract:Artemisinin and its derivatives have been widely applied as the most effective drugs in the treatment of malaria since their introduction in the last century. However, challenges such as short half-life, limited bioavailability, and increasing drug resistance have prompted researchers to explore new strategies in the development of antimalarial drugs. In this study, a nano-targeting drug delivery system (HEP@ART@NEs) is developed consisted of heparin as the outer shell and artemisinin in the inner core, utilizing a high-pressure homogenization approach. The specific targeting effect of HEP@ART@NEs is achieved through surface multivalent interactions between heparin with both Plasmodium falciparum merozoites as well as the surface of infected red blood cells (iRBCs). The physical and chemical properties of HEP@ART@NEs, as well as its anti-malarial activity both in vitro and in vivo, are systematically investigated. HEP@ART@NEs demonstrate enhanced antimalarial effects, delay malaria recrudescence, and improve survivability in a rodent model with P. berghei ANKA infection compared to the treatment with conventional artemisinin treatment. Overall, this study indicates that HEP@ART@NEs hold promise as a platform for a rational design of targeted delivery of antimalarial drugs.
Cultivation and genetics of Artemisia annua L. for increased production of the antimalarial artemisinin

J.F.S. Ferreira,J. C. Laughlin,N. Delabays,P.M. de Magalhães

DOI: https://doi.org/10.1079/pgr200585

2005-08-01

Plant Genetic Resources

Abstract:Malaria has been treated for over 350 years with quinine and quinine-derived drugs. However, in several areas of the world, some strains of the malarial parasite Plasmodium falciparum have developed resistance against these drugs. Recently, the World Health Organization (WHO) recommended the use of artemisinin-combination treatments (ACT) as the first-line treatment for multidrug-resistant falciparum malaria. The WHO estimates that current supplies of artemisinin are sufficient for only 30 million ACT, and is foreseeing the need for 130–220 million ACT in 2005 (WHO, 2004). Current research on the production of synthetic artemisinin-like compounds by the Roll Back Malaria project, pharmaceutical companies and academia resulted in a promising synthetic artemisinin-like compound (OZ277) which is currently undergoing phase I clinical trials. In about 5 years this drug is expected to be approved and made available to the public, however, meeting current global demands for ACT depends on the immediate availability of affordable artemisinin-derived drugs. This will involve expansion of the area under cultivation of Artemisia annua and improved methods of cultivation and processing of raw material, associated with more efficient methods for extraction and purification of artemisinin from plant material. This review addresses the agricultural, environmental and genetic aspects that may be useful in the successful large-scale cultivation of A. annua and for producing the antimalarial artemisinin in areas where it is urgently needed today. It also includes geographic aspects (latitude and altitude), which will help make decisions about crop establishment in tropical countries, and includes a list of Good Agricultural and Collection Practices for A. annua .
Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection

Yonglin Zhou,Baichen Liu,Xiuling Chu,Jianqing Su,Lei Xu,Li Li,Xuming Deng,Dan Li,Qianghua Lv,Jianfeng Wang

DOI: https://doi.org/10.1038/s42003-022-03898-5

IF: 6.548

2022-09-08

Communications Biology

Abstract:Abstract The emergence and spread of the mcr-1 gene and its mutants has immensely compromised the efficient usage of colistin for the treatment of drug-resistant Gram-negative bacterial infection in clinical settings. However, there are currently no clinically available colistin synergis. Here we identify artemisinin derivatives, such as dihydroartemisinin (DHA), that produces a synergistic antibacterial effect with colistin against the majority of Gram-negative bacteria (FIC < 0.5) without induced resistance, particularly those carrying the mcr-1 gene. Mechanism analysis reveals the direct engagement of DHA with the active center of MCR-1 to inhibit the activity of MCR-1. Meanwhile, the results from transcriptome and electron microscope analysis show that DHA could also simultaneously affect the flagellar assembly and the energy metabolism of bacteria. Moreover, in the mouse infection models of Gram-negative bacteria, combination therapy shows remarkable treatment benefits, as shown by an improved survival rate, reduced morbidity, alleviated pathological injury and decreased bacterial loading. Due to the generally safe profile of specialized malaria medication administration in humans, artemisinin derivatives are a promising class of multi-target inhibitors on bacterial resistance and virulence that can be used to extend the usage life of colistin and to tackle the inevitability of serious bacterial infection with colistin.

biology
Isolation of Dihydroartemisinic Acid from Artemisia annua L. By-Product by Combining Ultrasound-Assisted Extraction with Response Surface Methodology

Shuoqian Liu,Jorge Freire da Silva Ferreira,Liping Liu,Yuwei Tang,Dongming Tian,Zhonghua Liu,Na Tian

DOI: https://doi.org/10.1248/cpb.c17-00192

2017-08-01

Abstract:Malaria is the most devastating parasitic disease worldwide. Artemisinin is the only drug that can cure malaria that is resistant to quinine-derived drugs. After the commercial extraction of artemisinin from Artemisia annua, the recovery of dihydroartemisinic acid (DHAA) from artemisinin extraction by-product has the potential to increase artemisinin commercial yield. Here we describe the development and optimization of an ultrasound-assisted alkaline procedure for the extraction of DHAA from artemisinin production waste using response surface methodology. Our results using this methodology established that NaOH at 0.36%, extraction time of 67.96 min, liquid-solid ratio of 5.89, and ultrasonic power of 83.9 W were the optimal conditions to extract DHAA from artemisinin production waste. Under these optimal conditions, we achieved a DHAA yield of 2.7%. Finally, we conducted a validation experiment, and the results confirmed the prediction generated by the regression model developed in this study. This work provides a novel way to increase the production of artemisinin per cultivated area and to reduce artemisinin production costs by recycling its commercial waste to obtain DHAA, an immediate precursor of artemisinin. The use of this technology may reduce the costs of artemisinin-based antimalarial medicines.
Enhanced Antimalarial Activity of Extracts of Artemisia annua L. Achieved with Aqueous Solutions of Salicylate Salts and Ionic Liquids

Ana M Ferreira,Isabela Sales,Sónia A O Santos,Tiago Santos,Fátima Nogueira,Silvana Mattedi,Simão P Pinho,João A P Coutinho,Mara G Freire

DOI: https://doi.org/10.1021/cbe.3c00005

2024-01-04

Abstract:Artemisinin, a drug used to treat malaria, can be chemically synthesized or extracted from Artemisia annua L. However, the extraction method for artemisinin from biomass needs to be more sustainable while maintaining or enhancing its bioactivity. This work investigates the use of aqueous solutions of salts and ionic liquids with hydrotropic properties as alternative solvents for artemisinin extraction from Artemisia annua L. Among the investigated solvents, aqueous solutions of cholinium salicylate and sodium salicylate were found to be the most promising. To optimize the extraction process, a response surface method was further applied, in which the extraction time, hydrotrope concentration, and temperature were optimized. The optimized conditions resulted in extraction yields of up to 6.50 and 6.44 mg·g-1, obtained with aqueous solutions of sodium salicylate and cholinium salicylate, respectively. The extracts obtained were tested for their antimalarial activity, showing a higher efficacy against the Plasmodium falciparum strain compared with pure (synthetic) artemisinin or extracts obtained with conventional organic solvents. Characterization of the extracts revealed the presence of artemisinin together with other compounds, such as artemitin, chrysosplenol D, arteannuin B, and arteannuin J. These compounds act synergistically with artemisinin and enhance the antimalarial activity of the obtained extracts. Given the growing concern about artemisinin resistance, the results here obtained pave the way for the development of sustainable and biobased antimalarial drugs.

Treatment of Tardive Dyskinesia with Aripiprazole

Increased artemisinin production in Artemisia annua L. by co-overexpression of six key biosynthetic enzymes

Biotechnological Approaches for Production of Artemisinin, an Anti-Malarial Drug from Artemisia annua L

Developmental Iodine Deficiency and Hypothyroidism Impair Neural Development, Upregulate Caveolin-1, and Downregulate Synaptotagmin-1 in the Rat Cerebellum

Molecular Farming in Artemisia annua, a Promising Approach to Improve Anti-malarial Drug Production

Production of the antimalarial drug precursor artemisinic acid in engineered yeast

Enhancing artemisinin content in and delivery from Artemisia annua: a review of alternative, classical, and transgenic approaches

Tentative identification and influence of sterols and dimethyl sulf-oxide (DMSO) on the growth and survival of Fusarium roseum.

Combined chemical transformation and biological transformation of artemisinin: A facile approach to diverse artemisinin derivatives

Advanced metabolic engineering strategies for increasing artemisinin yield in Artemisia annua L

High-level semi-synthetic production of the potent antimalarial artemisinin

Induction of multiple pleiotropic drug resistance genes in yeast engineered to produce an increased level of anti-malarial drug precursor, artemisinic acid

Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development

Plant-based nanoparticles targeting malaria management

Pharmacokinetic study of intravenously administered artemisinin-loaded surface-decorated amphiphilic γ-cyclodextrin nanoparticles

Development, characterization, and evaluation of withaferin-A and artesunate-loaded pH-responsive acetal-dextran polymeric nanoparticles for the management of malaria

Improved Anti-Malarial Parasite Efficacy with Heparin-Artemisinin Nanoemulsions

Cultivation and genetics of Artemisia annua L. for increased production of the antimalarial artemisinin

Commercialized artemisinin derivatives combined with colistin protect against critical Gram-negative bacterial infection

Isolation of Dihydroartemisinic Acid from Artemisia annua L. By-Product by Combining Ultrasound-Assisted Extraction with Response Surface Methodology

Enhanced Antimalarial Activity of Extracts of Artemisia annua L. Achieved with Aqueous Solutions of Salicylate Salts and Ionic Liquids